Johnson & Johnson (NYSE:JNJ) reportedly has an opportunity to challenge the scientific evidence linking talc to ovarian cancer, as U.S. District Judge Michael Shipp ruled on Wednesday.
In January, Johnson & Johnson announced a tentative settlement to address investigations by 42 U.S. states and Washington, D.C., regarding alleged misleading information about the safety of its talc products linked to cancer cases. The pharmaceutical giant is set to pay approximately $700 million.
This ruling, potentially affecting over 53,000 lawsuits against the company, follows recent legal and scientific developments necessitating a fresh evaluation of the evidence.
Shipp, who took over the case in ...